» Articles » PMID: 17095337

Genetic and Physiologic Correlates of Longitudinal Immunoreactive Trypsinogen Decline in Infants with Cystic Fibrosis Identified Through Newborn Screening

Overview
Journal J Pediatr
Specialty Pediatrics
Date 2006 Nov 11
PMID 17095337
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To characterize the time course and physiologic significance of decline in serum immunoreactive trypsinogen (IRT) levels in infants with cystic fibrosis (CF) by mode of diagnosis and genotype, and to examine IRT heritability.

Study Design: We studied longitudinal IRT measurements in 317 children with CF. We developed statistical models to describe IRT decline. Pancreatic disease severity (Mild or Severe) was assigned using CF genotype and was confirmed in 47 infants through fat malabsorption studies.

Results: Infants with severe disease exhibited IRT decline with non-detectable levels typically seen by 5 years of age. Infants with mild disease exhibited a decline in the first 2 years, asymptomatically approaching a level greater than published norms. IRT and fecal fat were inversely correlated. IRT values in infants with meconium ileus (MI) were significantly lower than newborn-screened infants at birth. The high proportion of shared variation in predicted IRT values among sibling pairs with severe disease suggests that IRT is heritable.

Conclusions: IRT declines characteristically in infants with CF. Lower IRT values in newborns with MI suggest increased pancreatic injury. Furthermore, IRT is heritable among patients with severe disease suggesting genetic modifiers of early CF pancreatic injury. This study demonstrates heritability of a statistically modeled quantitative phenotype.

Citing Articles

Newborn Screening Program for Cystic Fibrosis in Türkiye: Experiences from False-Negative Tests and Requirement for Optimization.

Coksuer F, Kartal Ozturk G, Duman Senol H, Barlik M, Ozaslan M, Girgin Dindar B Balkan Med J. 2024; 42(1):45-53.

PMID: 39574132 PMC: 11725669. DOI: 10.4274/balkanmedj.galenos.2024.2024-7-144.


Missed Cystic Fibrosis Newborn Screening Cases due to Immunoreactive Trypsinogen Levels below Program Cutoffs: A National Survey of Risk Factors.

Kharrazi M, Sacramento C, Marie Comeau A, Hale J, Caggana M, Kay D Int J Neonatal Screen. 2022; 8(4).

PMID: 36412584 PMC: 9680406. DOI: 10.3390/ijns8040058.


High-quality read-based phasing of cystic fibrosis cohort informs genetic understanding of disease modification.

Mastromatteo S, Chen A, Gong J, Lin F, Thiruvahindrapuram B, Sung W HGG Adv. 2022; 4(1):100156.

PMID: 36386424 PMC: 9647008. DOI: 10.1016/j.xhgg.2022.100156.


Genetic Modifying Factors of Cystic Fibrosis Phenotype: A Challenge for Modern Medicine.

Butnariu L, Tarca E, Cojocaru E, Rusu C, Moisa S, Leon Constantin M J Clin Med. 2021; 10(24).

PMID: 34945117 PMC: 8707808. DOI: 10.3390/jcm10245821.


It All Depends What You Count-The Importance of Definitions in Evaluation of CF Screening Performance.

Heather N, Webster D Int J Neonatal Screen. 2020; 6(2):47.

PMID: 33073037 PMC: 7423005. DOI: 10.3390/ijns6020047.